Akoya Biosciences Inc

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Akoya Biosciences achieves record revenue, eyes strategic growth initiatives

Akoya Biosciences reported impressive financial performance and outlined strategic priorities for 2023, focusing on revenue growth and operational enhancements.
While facing challenges like anemic reagent revenue and increasing expenses, the company remains optimistic about its position for growth and market opportunities.
With a strong emphasis on partnerships, product innovation, and revenue diversification, Akoya is poised to leverage its strengths and navigate challenges for sustained success.

Akoya Biosciences reports record Q1 revenue and eyes sustained growth

Akoya Biosciences' Q1 performance reflects strong revenue growth and strategic focus on sustained high growth.
The company aims for cash flow positivity by 2025 through targeted spending and revenue growth.
Challenges include successful Fusion 2.0 upgrades and driving reagent growth, balanced with maintaining high performance.
Opportunities lie in upgrading customers, partnerships, and innovative solutions driving revenue growth.

Akoya Biosciences reports record Q2 revenue and strategic growth plans

Akoya Biosciences excelled in Q2 2023 with record revenue and system placements, showcasing strength in spatial biology solutions.
The company's focus on reagent revenue growth, system upgrades, and revenue guidance highlights a strategic path for future growth.
While facing challenges in gross margins and adoption methodologies, Akoya's investments and opportunities position it well for continued success.

Akoya Biosciences excels in Q3, eyes sustained growth and efficiency

Akoya Biosciences delivered a standout performance in Q3 2023, marked by record revenue and gross profit, supported by a robust install base and strategic initiatives.
The company's strengths lie in workflow efficiency enhancements, strong gross margins, and a clear growth strategy through services and partnerships.
Challenges include achieving cash flow positivity, sustaining margins, and driving adoption of new solutions, while opportunities abound in genomics, partnerships, and market expansion.
Overall, Akoya's focus on innovation, efficiency, and market positioning sets a solid foundation for continued growth and financial success.

Akoya Biosciences reports record-breaking revenue and strategic partnerships for growth

Akoya Biosciences delivered impressive financial performance in Q4 2023, showcasing revenue growth, cost management, and strategic investments. While facing challenges from macro pressures and underperformance in certain regions, the company remains focused on achieving cash flow breakeven by 2024. Akoya's strengths in partnerships and product enhancements position them well for continued growth and margin expansion.

Akoya Biosciences reports Q1 revenue decline but eyes growth opportunities

Akoya Biosciences faced revenue decline in Q1 due to weak instrument placements but saw growth in reagent and services revenue, aiming for breakeven by year-end.
The company updated its 2024 revenue outlook, expecting a measured recovery and sustained growth, with opportunities in partnerships and margin improvement initiatives.
Challenges include academic budget assumptions impacting revenue guidance and increasing outsourcing to CROs affecting reagent growth opportunities.
Despite challenges, Akoya's strengths lie in strong reagent revenue growth, strategic partnerships, and potential for achieving higher gross margins in the future.

Akoya Biosciences reports strong Q2 revenue growth and eyes market expansion

Akoya Biosciences demonstrated robust revenue growth in Q2 2024, driven by strong performance across instrument, reagent, and service segments.
While facing challenges in revenue guidance adjustments and delayed impact from NMPA approval in China, Akoya's strategic initiatives and product strengths offer promising opportunities for future growth.
Overall, Akoya's focus on financial goals, product innovation, and market expansion sets a positive trajectory for the company's performance and competitiveness in the biotech sector.

Akoya Biosciences reports Q3 revenue dip, focuses on strategic growth

Akoya Biosciences faced revenue challenges in Q3 2024 but showed operational improvements and strategic advancements.
The company is focused on enhancing efficiency, expanding product offerings, and leveraging partnerships for growth.
While navigating competitive pressures and cash flow concerns, Akoya Biosciences aims for sustainable profitability and market leadership.
Strategic initiatives, stable gross margins, and a strong leadership team position Akoya Biosciences for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MARLBOROUGH, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021.

Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

Alnylam Pharmaceuticals

Biohaven Pharmaceutical Hld

Sanofi

These biotech stocks could be worth watching in 2022.

Which Stocks To Buy Now? 4 Biotech Stocks To Know

Akoya's powerful new PhenoCycler™-Fusion system combined with Bio-Techne's proven and established RNAScope® technology will enable comprehensive spatial phenotyping of RNA and protein biomarkers Akoya's powerful new PhenoCycler™-Fusion system combined with Bio-Techne's proven and established RNAScope® technology will enable comprehensive spatial phenotyping of RNA and protein biomarkers

Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution

Bio-Techne

MINNEAPOLIS  and MARLBOROUGH, Mass., Jan. 5, 2022 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples.

Bio-Techne and Akoya Biosciences Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution

MARLBOROUGH, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the 40th Annual J.P. Morgan Healthcare Conference.

Akoya Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

-Company previews an integrated suite of solutions, including the new PhenoCycler ™ -Fusion System  for unbiased spatial discovery, at unprecedented speeds

Akoya Biosciences Unveils Comprehensive Roadmap of Innovations at Inaugural Spatial Day Event

Partnership pairs Akoya's spatial phenotyping solutions and PathAI's AI-based algorithms to elucidate spatial biomarker signatures for biopharma partners Partnership pairs Akoya's spatial phenotyping solutions and PathAI's AI-based algorithms to elucidate spatial biomarker signatures for biopharma partners

Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers

Certification ensures Akoya's cutting-edge spatial biology tools meet the highest standards for translational medicine and clinical research, with longer term potential for companion diagnostics.

Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying Its Spatial Biology Technologies to Accelerating Precision Cancer Therapies

The program will highlight the latest breakthroughs and applications in spatial biology and the company's latest innovations to accelerate breakthroughs in discovery and clinical research.

Akoya Biosciences to Host Inaugural Spatial Day on December 15, 2021

Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q3 2021 Earnings Call Transcript

Q3 revenue $13.5 million, the highest in Akoya's history and an increase of 35% over prior year Q3 revenue $13.5 million, the highest in Akoya's history and an increase of 35% over prior year

Akoya Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Guidance

Presentations by the company and customers will offer insights on how spatial phenotypic signatures can accelerate immuno-oncology biomarker development Presentations by the company and customers will offer insights on how spatial phenotypic signatures can accelerate immuno-oncology biomarker development

Akoya Biosciences to Present Data at SITC 2021 Highlighting Novel Spatial Biology Applications

MARLBOROUGH, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in two upcoming investor conferences.

Akoya to Participate at Two Upcoming Investor Conferences in November

I 2 Investigators will leverage CODEX technology and the expertise of Akoya and its partners as they push the boundaries of spatial biology.

Akoya Biosciences Announces Founding Members of First-of-its-Kind Imaging Innovators (I²) Network

Accomplished leader in laboratory innovations and diagnostics Accomplished leader in laboratory innovations and diagnostics

Akoya Biosciences Appoints Pascal Bamford, PhD, as SVP, R&D and Laboratory Operations

MARLBOROUGH, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2021 after the market close on Monday, November 8th, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report Third Quarter 2021 Financial Results on November 8th, 2021

MARLBOROUGH, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true pioneer and leader in the diagnostic industry, to its board of directors.

Akoya Biosciences Appoints Diagnostics Industry Pioneer Myla Lai-Goldman, MD, to its Board of Directors

MARLBOROUGH, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q2 2021 Results - Earnings Call Transcript

MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2021.

Akoya Reports 53% Revenue Growth in the Second Quarter of 2021

MARLBOROUGH, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Canaccord 41st Annual Growth Conference.

Akoya Biosciences to Present at the Canaccord 41st Annual Growth Conference

MARLBOROUGH, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2021 after the market close on Tuesday, August 10, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report Second Quarter 2021 Financial Results on August 10, 2021

Results from the study provide evidence of standardization of an automated spatial biology workflow, based on the company's Phenoptics™ multiplex immunofluorescence (mIF) platform, for clinical and translational research Results from the study provide evidence of standardization of an automated spatial biology workflow, based on the company's Phenoptics™ multiplex immunofluorescence (mIF) platform, for clinical and translational research

Akoya Announces Publication of the MITRE Study, the First Multi-Institutional Analytical Demonstration of a Spatial Biology Workflow, in the Journal for ImmunoTherapy of Cancer

ROME, Italy--(BUSINESS WIRE)--CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced that it has been selected by Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, as a premier microscope provider to jointly develop new spatial biology and spatial phenotyping applications. CrestOptics has been invited to the partnership among other leading companies in the field of imagi

CrestOptics Selected by Akoya Biosciences for Spatial Biology Collaboration

Company plans to work with multiple microscope partners to broaden access to the CODEX® solution for single-cell, multiplexed imaging Company plans to work with multiple microscope partners to broaden access to the CODEX® solution for single-cell, multiplexed imaging

News for Akoya Biosciences Inc Stock (AKYA)